Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic CancerSusan Tsai, Douglas B. Evans, Ben George et al.|Annals of Surgery|2018Cited by 237
A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal AdenocarcinomaSusan Tsai, Douglas B. Evans, Syed A. Ahmad et al.|Annals of Surgery|2018Cited by 72
Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgeryChad A. Barnes, Kathleen K. Christians, Mariana Chávez et al.|Surgery|2019Cited by 63
Evolution of the Management of Resectable Pancreatic CancerSusan Tsai, Douglas B. Evans, Bradley A. Erickson et al.|Journal of Oncology Practice|2016Cited by 31
Development of a high risk pancreatic screening clinic using 3.0 T MRIChad A. Barnes, Susan Tsai, Elizabeth A. Krzywda et al.|Familial Cancer|2017Cited by 28